PRQR - プロキュ―ア―ル・セラピュ―ティクス （ProQR Therapeutics N.V.）PRQRのニュース
Citi maintains ProQR Therapeutics NV at ''neutral'' with a price target of $2.10 2023/05/26 10:24:58 Investing.com
https://www.investing.com/news/pro/proqr-thera-receives-investment-bank-analyst-rating-update-3091869
Cantor Fitzgerald maintains ProQR Therapeutics NV at ''overweight'' with a price target of $4.50 2023/05/17 10:34:40 Investing.com
https://www.investing.com/news/pro/proqr-thera-receives-investment-bank-analyst-rating-update-3084563
Leber Congenital Amaurosis Market to Expand at a Significant Growth Rate During the Forecast Period (2022-32) - Estimates DelveInsight | ProQR Therapeutics, IVERIC bio, MeiraGTx, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies 2023/04/26 19:18:56 OpenPR
As per DelveInsight, the Leber Congenital Amaurosis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Leber congenital amaurosis patients in the 7MM and the launch of new therapies in the market.
Why Shares of ProQR Therapeutics Dropped on Wednesday 2023/03/29 16:30:55 The Motley Fool
The clinical-stage biotech released fourth-quarter and full-year earnings.
Kodiak, Arcturus top healthcare gainers; ProQR, Sharecare among losers 2023/03/29 14:05:07 Seeking Alpha
Kodiak Sciences (KOD) +19%. Arcturus Therapeutics (ARCT) +16%. ProQR Therapeutics (PRQR) -31%. Sharecare (SHCR) -29%.
Leber Congenital Amaurosis Market to Expand at a Significant Growth Rate During the Forecast Period (2022-32) - Estimates DelveInsight | ProQR Therapeutics, IVERIC bio, MeiraGTx, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies 2023/04/26 19:18:56 OpenPR
As per DelveInsight, the Leber Congenital Amaurosis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Leber congenital amaurosis patients in the 7MM and the launch of new therapies in the market.
Why Shares of ProQR Therapeutics Dropped on Wednesday 2023/03/29 16:30:55 The Motley Fool
The clinical-stage biotech released fourth-quarter and full-year earnings.
Kodiak, Arcturus top healthcare gainers; ProQR, Sharecare among losers 2023/03/29 14:05:07 Seeking Alpha
Kodiak Sciences (KOD) +19%. Arcturus Therapeutics (ARCT) +16%. ProQR Therapeutics (PRQR) -31%. Sharecare (SHCR) -29%.
Earnings Outlook For ProQR Therapeutics 2023/03/28 14:02:48 Benzinga
ProQR Therapeutics (NASDAQ: PRQR ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-29. Here''s what investors need to know before the announcement. Analysts estimate that ProQR Therapeutics will report an earnings per share (EPS) of $-0.18. ProQR Therapeutics bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Currently -31.25% Below Its 52-Week High But The Downside Potential May Surprise You 2023/03/10 17:00:00 Marketing Sentinel
In recent trading session, ProQR Therapeutics N.V. (NASDAQ:PRQR) saw 0.25 million shares changing hands at last check today with its beta currently measuring 0.09. Company’s recent per share price level of $2.88 trading at -$0.3 or -9.43% at last check today assigns it a market valuation of $219.48M. That most recent trading price of PRQR’s … ProQR Therapeutics N.V. (NASDAQ:PRQR) Currently -31.25% Below Its 52-Week High But The Downside Potential May Surprise You Read More »
How should investors view ProQR Therapeutics N.V. (PRQR)? 2023/01/03 13:48:00 US Post News
A share of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at $3.70 per share on Friday, up from $3.37 day before. While ProQR Therapeutics N.V. has overperformed by 9.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -54.71%, with highs and lows ranging from $8.60 […]
A stock that deserves closer examination: ProQR Therapeutics N.V. (PRQR) 2022/12/27 13:16:00 US Post News
ProQR Therapeutics N.V. (NASDAQ:PRQR) closed Friday at $2.71 per share, up from $2.70 a day earlier. While ProQR Therapeutics N.V. has overperformed by 0.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -66.95%, with highs and lows ranging from $8.60 to $0.53, whereas […]
ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Forecast: Bullish Signals Pointing To $5.00 In 2022 2022/12/27 12:30:00 Marketing Sentinel
In the last trading session, 5.55 million shares of the ProQR Therapeutics N.V. (NASDAQ:PRQR) were traded, and its beta was 0.48. Most recently the company’s share price was $2.71, and it changed around $0.01 or 0.37% from the last close, which brings the market valuation of the company to $192.90M. PRQR currently trades at a … ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Forecast: Bullish Signals Pointing To $5.00 In 2022 Read More »